Sareum Holdings


£56.4m market cap

1.73p last close

Sareum is a UK company with a discovery-stage oncology pipeline and a profitable fee-for-service business providing structure-based drug discovery.

Investment summary

The bulk of Sareum’s value rests on the late preclinical autoimmune therapy SDC-1801, with planned filing to start clinical development in H121 followed by possible exploratory clinical studies, if funding allows, from H221. This could open the way to a substantive partnering deal from Q222. Partnering could be helped if the related BMS therapeutic deucravacitinib gains FDA approval and blockbuster sales in psoriasis. Sareum could offer a partner a promising route to an autoimmune therapy with potentially broad indications.

Register to receive research on Sareum Holdings as it is published
Share price graph
Price performance
Actual (13.8) 11.3 379.2
Relative* (14.0) 6.6 404.8
52-week high/low 2.5p/0.2p
*% relative to local index
Key management
Tim Mitchell CEO
John Reader CSO
Stephen Parker Non-executive chairman